Nothing Special   »   [go: up one dir, main page]

ATE332689T1 - Therapeutische zusammensetzungen, enthaltend amlodipin und atorvastatin - Google Patents

Therapeutische zusammensetzungen, enthaltend amlodipin und atorvastatin

Info

Publication number
ATE332689T1
ATE332689T1 AT04013754T AT04013754T ATE332689T1 AT E332689 T1 ATE332689 T1 AT E332689T1 AT 04013754 T AT04013754 T AT 04013754T AT 04013754 T AT04013754 T AT 04013754T AT E332689 T1 ATE332689 T1 AT E332689T1
Authority
AT
Austria
Prior art keywords
atorvastatin
compositions containing
therapeutic compositions
containing amlodipine
amlodipine
Prior art date
Application number
AT04013754T
Other languages
English (en)
Inventor
Jan Buch
Robert Andrew Donald Scott
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22009597&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE332689(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Application granted granted Critical
Publication of ATE332689T1 publication Critical patent/ATE332689T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4422—1,4-Dihydropyridines, e.g. nifedipine, nicardipine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Mycology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pulmonology (AREA)
  • Microbiology (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT04013754T 1997-08-29 1998-08-11 Therapeutische zusammensetzungen, enthaltend amlodipin und atorvastatin ATE332689T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US5727597P 1997-08-29 1997-08-29

Publications (1)

Publication Number Publication Date
ATE332689T1 true ATE332689T1 (de) 2006-08-15

Family

ID=22009597

Family Applications (2)

Application Number Title Priority Date Filing Date
AT04013754T ATE332689T1 (de) 1997-08-29 1998-08-11 Therapeutische zusammensetzungen, enthaltend amlodipin und atorvastatin
AT98936587T ATE277615T1 (de) 1997-08-29 1998-08-11 Therapeutische zusammensetzungen, enthaltend amlopidin und atorvastatin

Family Applications After (1)

Application Number Title Priority Date Filing Date
AT98936587T ATE277615T1 (de) 1997-08-29 1998-08-11 Therapeutische zusammensetzungen, enthaltend amlopidin und atorvastatin

Country Status (49)

Country Link
US (11) US6455574B1 (de)
EP (3) EP1003503B1 (de)
JP (3) JP2001514222A (de)
KR (1) KR20010023498A (de)
CN (2) CN101062035A (de)
AP (1) AP1225A (de)
AR (1) AR012269A1 (de)
AT (2) ATE332689T1 (de)
AU (1) AU755636B2 (de)
BG (1) BG64665B1 (de)
BR (1) BR9812030A (de)
CA (1) CA2301732C (de)
CO (1) CO4970694A1 (de)
CY (2) CY1105108T1 (de)
CZ (1) CZ301081B6 (de)
DE (2) DE69835245T2 (de)
DK (2) DK1003503T3 (de)
DZ (1) DZ2596A1 (de)
EA (1) EA003549B1 (de)
ES (2) ES2227865T3 (de)
GE (2) GEP20084338B (de)
GT (1) GT199800127A (de)
HN (1) HN1998000132A (de)
HR (1) HRP980473B1 (de)
HU (1) HUP0003656A3 (de)
ID (1) ID23670A (de)
IL (2) IL134303A0 (de)
IS (1) IS2029B (de)
LU (1) LU91253I2 (de)
MA (1) MA26535A1 (de)
ME (1) ME00545B (de)
MY (1) MY123993A (de)
NO (1) NO320267B1 (de)
NZ (2) NZ527158A (de)
OA (1) OA11290A (de)
PA (1) PA8457101A1 (de)
PE (1) PE107199A1 (de)
PL (1) PL192360B1 (de)
PT (2) PT1003503E (de)
RS (1) RS50485B (de)
SI (2) SI1491193T1 (de)
SK (1) SK284958B6 (de)
TN (1) TNSN98156A1 (de)
TR (1) TR200000561T2 (de)
TW (1) TW592696B (de)
UA (1) UA71897C2 (de)
UY (1) UY25157A1 (de)
WO (1) WO1999011259A1 (de)
ZA (1) ZA987844B (de)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6262277B1 (en) 1994-09-13 2001-07-17 G.D. Searle And Company Intermediates and processes for the preparation of benzothiepines having activity as inhibitors of ileal bile acid transport and taurocholate uptake
US6642268B2 (en) 1994-09-13 2003-11-04 G.D. Searle & Co. Combination therapy employing ileal bile acid transport inhibiting benzothipines and HMG Co-A reductase inhibitors
UA53716C2 (uk) 1997-06-25 2003-02-17 Пфайзер Продактс Інк. Тартратна сіль заміщеного дипептиду, спосіб її одержання, проміжні сполуки та спосіб їх одержання, фармацевтична композиція (варіанти), спосіб підвищення рівнів ендогенного гормону росту та спосіб лікування або профілактики захворювань (варіанти)
GT199800127A (es) * 1997-08-29 2000-02-01 Combinaciones terapeuticas.
ES2256005T3 (es) * 1999-04-23 2006-07-16 R. Preston Mason Efectos sinergicos de amlodipina y del metabolito hidroxilado de atorvastatin.
US7129265B2 (en) * 1999-04-23 2006-10-31 Mason R Preston Synergistic effects of amlodipine and atorvastatin metabolite as a basis for combination therapy
EP1180102B9 (de) 1999-05-27 2005-03-02 Pfizer Products Inc. Gegenseitige prodrugs von amlopidin und atorvastatin
HN2000000050A (es) 1999-05-27 2001-02-02 Pfizer Prod Inc Sal mutua de amlodipino y atorvastatina
CA2314517A1 (en) * 1999-07-26 2001-01-26 Gust H. Bardy System and method for determining a reference baseline of individual patient status for use in an automated collection and analysis patient care system
EA200200240A1 (ru) 1999-10-11 2002-10-31 Пфайзер Инк. 5-(2-ЗАМЕЩЕННЫЕ-5-ГЕТЕРОЦИКЛИЛСУЛЬФОНИЛПИРИД-3-ИЛ)-ДИГИДРОПИРАЗОЛО[4,3-d]ПИРИМИДИН-7-ОНЫ В КАЧЕСТВЕ ИНГИБИТОРОВ ФОСФОДИЭСТЕРАЗЫ
US6336903B1 (en) 1999-11-16 2002-01-08 Cardiac Intelligence Corp. Automated collection and analysis patient care system and method for diagnosing and monitoring congestive heart failure and outcomes thereof
US20050119270A1 (en) * 2000-08-04 2005-06-02 Mason R. P. Synergistic effect of amlodipine and atorvastatin on aortic endothelial cell nitric oxide release
US6835742B2 (en) * 2000-08-04 2004-12-28 R. Preston Mason Synergistic effect of amlodipine and atorvastatin on cholesterol crystal formation inhibition and aortic endothelial cell nitric oxide release
WO2002017913A1 (fr) * 2000-08-30 2002-03-07 Sankyo Company, Limited Compositions medicinales utilisees dans la prevention ou le traitement de l'insuffisance cardiaque
US6737430B2 (en) 2000-11-09 2004-05-18 Pfizer, Inc. Mutual prodrug of amlodipine and atorvastatin
GB0027410D0 (en) * 2000-11-09 2000-12-27 Pfizer Ltd Mutual prodrug of amlodipine and atorvastatin
PE20030324A1 (es) * 2001-07-31 2003-04-03 Warner Lambert Co Composiciones farmaceuticas de amlodipina y atorvastatina
US20030044459A1 (en) * 2001-09-04 2003-03-06 Pfizer Inc. Biomodulated multiparticulate formulations
US7670612B2 (en) 2002-04-10 2010-03-02 Innercap Technologies, Inc. Multi-phase, multi-compartment capsular delivery apparatus and methods for using same
US20040053842A1 (en) * 2002-07-02 2004-03-18 Pfizer Inc. Methods of treatment with CETP inhibitors and antihypertensive agents
US7071210B2 (en) * 2002-07-02 2006-07-04 Pfizer Inc. CETP inhibitors in combination with antihypertensive agents and uses thereof
US20050182106A1 (en) * 2002-07-11 2005-08-18 Sankyo Company, Limited Medicinal composition for mitigating blood lipid or lowering blood homocysteine
US20040198789A1 (en) * 2003-02-28 2004-10-07 Recordati Ireland Limited Lercanidipine/ARB/diuretic therapeutic combinations
US20040248972A1 (en) * 2003-05-16 2004-12-09 Ambit Biosciences Corporation Compounds and uses thereof
JP2007516227A (ja) * 2003-05-16 2007-06-21 アンビット バイオサイエンシス コーポレーション ピロール化合物およびその使用
US20050182125A1 (en) * 2003-05-16 2005-08-18 Ambit Biosciences Corporation Pyrrole compounds and uses thereof
US20040253305A1 (en) * 2003-06-12 2004-12-16 Luner Paul E. Pharmaceutical compositions of atorvastatin
US20050271717A1 (en) * 2003-06-12 2005-12-08 Alfred Berchielli Pharmaceutical compositions of atorvastatin
WO2005097191A2 (en) * 2004-04-04 2005-10-20 Sepracor Inc. COMBINATIONS COMPRISING (S)- AMLODIPINE AND A HMG-CoA REDUCTASE INHIBITOR OR CHOLESTEROL ABSORPOTION INHIBITOR OR BOTH, AND METHODS FOR REDUCING HYPERTENSION
DE602005018387D1 (de) * 2004-10-06 2010-01-28 Eisai R&D Man Co Ltd Medizinische zusammensetzung, verfahren zu ihrer hdihydropyridin-verbindung in einer medizinischen zusammensetzung
CN101080232A (zh) 2004-12-15 2007-11-28 索尔瓦药物有限公司 包含NEP－抑制剂、内源性内皮素产生系统的抑制剂和HMG CoA还原酶抑制剂的药物组合物
KR100582347B1 (ko) * 2004-12-30 2006-05-22 한미약품 주식회사 3-하이드록시-3-메틸글루타릴 조효소 ａ 환원효소 억제제및 고혈압 치료제의 복합제제 및 그의 제조방법
EP2000137B1 (de) * 2006-03-29 2015-10-21 Kowa Company, Ltd. Mittel zur triglyzeridsenkung und mittel gegen hyperinsulinismus
JP2008044870A (ja) * 2006-08-11 2008-02-28 Elmed Eisai Kk 医薬組成物及びその製造方法
WO2008023869A1 (en) * 2006-08-24 2008-02-28 Hanall Pharmaceutical Co., Ltd. Combined pharmeceutical formulation with controlled-release comprising dihydropyridine calcium channel blockers and hmg-coa reductase inhibitors
PL2120878T3 (pl) 2007-02-09 2015-01-30 Alphapharm Pty Ltd Postać dawkowania zawierająca dwa czynne składniki farmaceutyczne o różnych postaciach fizycznych
EP2154958A4 (de) * 2007-05-03 2011-05-04 Anthera Pharmaceuticals Inc Behandlung von herz-kreislauf-krankheiten und dyslipidämie mit hemmern der sekretorischen phospholipase a2 (spla2) und spla2-hemmer-kombinationstherapien
US8048880B2 (en) * 2007-05-03 2011-11-01 Anthera Pharmaceuticals, Inc. Treatment of cardiovascular disease and dyslipidemia using secretory phospholipase A2 (SPLA2) inhibitors and SPLA2 inhibitor combination therapies
CN101433539A (zh) * 2007-11-12 2009-05-20 北京瑞康医药技术有限公司 含有烟酸氨氯地平和他汀类药物的治疗组合物
CN101433538B (zh) * 2007-11-12 2012-07-25 北京瑞康医药技术有限公司 含有氨氯地平和烟酸的治疗组合物
EP2161024A1 (de) 2008-09-05 2010-03-10 Universitätsklinikum Hamburg-Eppendorf Kombinationspräparat zur Behandlung von Krebs
IT1400309B1 (it) 2010-05-10 2013-05-24 Menarini Int Operations Lu Sa Associazione di inibitori della xantina ossidasi e calcio antagonisti e loro uso.
CN102755322B (zh) * 2012-07-24 2013-12-11 兆科药业（广州）有限公司 一种乐卡地平和阿托伐他汀复方制剂
CN105758967B (zh) * 2016-03-24 2017-10-27 中国药科大学 诊断区分冠状动脉粥样硬化和稳定型心绞痛的标志物群
CN110915354B (zh) * 2019-12-05 2021-11-23 重庆市农业科学院 一种马铃薯种薯自动切块机
US11452690B1 (en) 2021-01-27 2022-09-27 ECI Pharmaceuticals, LLC Oral liquid compositions comprising amlodipine besylate and methods of using the same

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5612114B2 (de) 1974-06-07 1981-03-18
US4231938A (en) 1979-06-15 1980-11-04 Merck & Co., Inc. Hypocholesteremic fermentation products and process of preparation
US4444784A (en) 1980-08-05 1984-04-24 Merck & Co., Inc. Antihypercholesterolemic compounds
DK149080C (da) 1980-06-06 1986-07-28 Sankyo Co Fremgangsmaade til fremstilling af derivater af ml-236b-carboxylsyre
US4450171A (en) 1980-08-05 1984-05-22 Merck & Co., Inc. Antihypercholesterolemic compounds
DK161312C (da) * 1982-03-11 1991-12-09 Pfizer Analogifremgangsmaade til fremstilling af 2-aminoalkoxymethyl-4-phenyl-6-methyl-1,4-dihydropyridin-3,5-dicarboxylsyreestere eller syreadditionssalte deraf samt phthalimidoderivater til anvendelse som udgangsmateriale ved fremgangsmaaden
US4448784A (en) 1982-04-12 1984-05-15 Hoechst-Roussel Pharmaceuticals, Inc. 1-(Aminoalkylphenyl and aminoalkylbenzyl)-indoles and indolines and analgesic method of use thereof
US4739073A (en) 1983-11-04 1988-04-19 Sandoz Pharmaceuticals Corp. Intermediates in the synthesis of indole analogs of mevalonolactone and derivatives thereof
US5208225A (en) * 1986-02-27 1993-05-04 Warner-Lambert Company Compositions containing fixed combinations
GB8608335D0 (en) * 1986-04-04 1986-05-08 Pfizer Ltd Pharmaceutically acceptable salts
US4681893A (en) * 1986-05-30 1987-07-21 Warner-Lambert Company Trans-6-[2-(3- or 4-carboxamido-substituted pyrrol-1-yl)alkyl]-4-hydroxypyran-2-one inhibitors of cholesterol synthesis
DE3807895A1 (de) 1988-03-10 1989-09-21 Knoll Ag Erzeugnisse, enthaltend einen calciumantagonisten und einen lipidsenker
US4804770A (en) 1988-04-29 1989-02-14 E. R. Squibb & Sons, Inc. Process for preparing a keto-phosphonate intermediate useful in preparing HMG-CoA reductase inhibitors
US5273985A (en) * 1988-07-04 1993-12-28 Eisai Co., Ltd. Glycerin derivative and its pharmacological use
SG139553A1 (en) 1988-10-13 2008-02-29 Novartis Ag 7-substituted-hept-6-enoic and -heptanoic acids and derivatives thereof
US4920123A (en) 1988-10-21 1990-04-24 Beyer Jr Karl H Method for controlling and/or lowering serum triglyceride and/or cholesterol levels in mammals
FI94339C (fi) * 1989-07-21 1995-08-25 Warner Lambert Co Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi
US5622985A (en) 1990-06-11 1997-04-22 Bristol-Myers Squibb Company Method for preventing a second heart attack employing an HMG CoA reductase inhibitor
US5155120A (en) * 1991-01-14 1992-10-13 Pfizer Inc Method for treating congestive heart failure
US5208037A (en) * 1991-04-22 1993-05-04 Alza Corporation Dosage forms comprising polymers comprising different molecular weights
DE4309553A1 (de) 1993-03-24 1994-09-29 Bayer Ag Verfahren zur Herstellung von 3R,5S-(+)-Natrium-erythro-(E)-7-(4-(4-flurophenyl)-2,6-diisopropyl-5-methoxymethyl-pyrid-3-yl)-3,5-dihydroxy-hept-6-enoat
IN176897B (de) 1993-10-29 1996-09-28 Cadila Lab Ltd
US5385929A (en) 1994-05-04 1995-01-31 Warner-Lambert Company [(Hydroxyphenylamino) carbonyl] pyrroles
US5447922A (en) * 1994-08-24 1995-09-05 Bristol-Myers Squibb Company α-phosphonosulfinic squalene synthetase inhibitors
EP0738510A3 (de) 1995-04-20 2005-12-21 L'oreal Verwendung eines HMG-CoA-Reduktase Inhibitors als Hautalterungschutzmittel und als Anti-Aknemittel. Zusammensetzung enthaltend mindestens einen HMG-CoA-Reduktase Inhibitor und mindestens einen Wirkstoff mit abschuppenden Eigenschaften
HUP9601808A3 (en) * 1995-07-03 2000-06-28 Sankyo Co Treatment of arteriosclerosis and xanthoma
DE19539363A1 (de) 1995-10-23 1997-04-24 Basf Ag Verfahren zur Herstellung von festen Arzneiformen
KR100449604B1 (ko) * 1995-11-02 2004-11-16 워너-램버트 캄파니 엘엘씨 지질농도를 조절하는 제약 조성물 및 방법
US6180660B1 (en) * 1997-08-26 2001-01-30 Merck & Co., Inc. Cholesterol-lowering therapy
GT199800126A (es) * 1997-08-29 2000-01-29 Terapia de combinacion.
GT199800127A (es) * 1997-08-29 2000-02-01 Combinaciones terapeuticas.
HN2000000050A (es) * 1999-05-27 2001-02-02 Pfizer Prod Inc Sal mutua de amlodipino y atorvastatina
EP1180102B9 (de) * 1999-05-27 2005-03-02 Pfizer Products Inc. Gegenseitige prodrugs von amlopidin und atorvastatin
US20030092745A1 (en) * 2000-02-25 2003-05-15 Pfizer Inc. Combination therapy
US7925624B2 (en) * 2006-03-31 2011-04-12 Amazon Technologies, Inc. System and method for providing high availability data

Also Published As

Publication number Publication date
US20030008904A1 (en) 2003-01-09
US20120208854A1 (en) 2012-08-16
AR012269A1 (es) 2000-09-27
TW592696B (en) 2004-06-21
HUP0003656A2 (en) 2001-03-28
SK2042000A3 (en) 2000-12-11
CN1268052A (zh) 2000-09-27
US20130131125A1 (en) 2013-05-23
CY1105108T1 (el) 2010-03-03
CY2007003I1 (el) 2009-11-04
DE69826683T2 (de) 2005-10-20
JP2001514222A (ja) 2001-09-11
DE69835245T2 (de) 2007-07-19
CY2007003I2 (el) 2009-11-04
HRP980473B1 (en) 2005-10-31
IL134303A (en) 2006-10-05
DK1491193T3 (da) 2006-10-16
PL192360B1 (pl) 2006-10-31
SK284958B6 (sk) 2006-03-02
US20140039017A1 (en) 2014-02-06
EP1491193B1 (de) 2006-07-12
AU8554898A (en) 1999-03-22
US20060223865A1 (en) 2006-10-05
US20090297598A1 (en) 2009-12-03
MY123993A (en) 2006-06-30
IS2029B (is) 2005-08-15
ME00545B (me) 2011-10-10
PE107199A1 (es) 1999-11-06
AP1225A (en) 2003-11-20
AP9801334A0 (en) 1998-09-30
EP1003503A1 (de) 2000-05-31
OA11290A (en) 2003-08-25
ID23670A (id) 2000-05-11
TR200000561T2 (tr) 2000-07-21
DE69835245D1 (de) 2006-08-24
PT1491193E (pt) 2006-10-31
JP2010111693A (ja) 2010-05-20
CA2301732A1 (en) 1999-03-11
ES2266961T3 (es) 2007-03-01
NO20000998D0 (no) 2000-02-28
ATE277615T1 (de) 2004-10-15
US20040048906A1 (en) 2004-03-11
CO4970694A1 (es) 2000-11-07
MA26535A1 (fr) 2004-12-20
US20100168187A1 (en) 2010-07-01
PL339092A1 (en) 2000-12-04
UA71897C2 (uk) 2005-01-17
ES2227865T3 (es) 2005-04-01
EA003549B1 (ru) 2003-06-26
TNSN98156A1 (fr) 2005-03-15
BG104177A (en) 2000-12-29
LU91253I2 (fr) 2006-08-21
GEP20084338B (de) 2008-03-25
US20060270717A1 (en) 2006-11-30
GEP20104874B (en) 2010-01-11
IS5343A (is) 2000-01-14
EP1003503B1 (de) 2004-09-29
UY25157A1 (es) 2000-12-29
SI1491193T1 (sl) 2006-10-31
NZ527158A (en) 2005-03-24
CA2301732C (en) 2005-03-29
DZ2596A1 (fr) 2003-02-22
YU2100A (sh) 2002-11-15
IL134303A0 (en) 2001-04-30
AU755636B2 (en) 2002-12-19
DE69826683D1 (de) 2004-11-04
NO20000998L (no) 2000-02-28
PA8457101A1 (es) 2000-05-24
HRP980473A2 (en) 1999-06-30
EA200000164A1 (ru) 2000-10-30
NZ537880A (en) 2007-04-27
US20110201654A1 (en) 2011-08-18
KR20010023498A (ko) 2001-03-26
ZA987844B (en) 2000-02-28
BR9812030A (pt) 2000-09-26
HUP0003656A3 (en) 2002-10-28
CZ301081B6 (cs) 2009-10-29
US6455574B1 (en) 2002-09-24
SI1003503T1 (en) 2004-12-31
RS50485B (sr) 2010-03-02
WO1999011259A1 (en) 1999-03-11
EP1468682A1 (de) 2004-10-20
CZ2000511A3 (cs) 2000-06-14
GT199800127A (es) 2000-02-01
DK1003503T3 (da) 2005-01-10
NO320267B1 (no) 2005-11-14
CN101062035A (zh) 2007-10-31
JP2004210797A (ja) 2004-07-29
HN1998000132A (es) 1999-02-09
EP1491193A1 (de) 2004-12-29
PT1003503E (pt) 2004-12-31
BG64665B1 (bg) 2005-11-30

Similar Documents

Publication Publication Date Title
ATE332689T1 (de) Therapeutische zusammensetzungen, enthaltend amlodipin und atorvastatin
ATE285767T1 (de) Kombinationstherapie, enthaltend atorvastatin und bluddrucksenkendes mittel
IS5345A (is) Samsett meðferð sem inniheldur amlódipín og statín efnasambönd
NO983635D0 (no) Dentalforbindelser, sammensetninger og produkter
IS5541A (is) Áfangatöflur til inntöku
BR9708677A (pt) Piperidinas e pirrolidinas
BR9509688A (pt) Composto e composição farmacêutica
ID29294A (id) Komposisi farmasi
ID25857A (id) Komposisi farmasi
ID18698A (id) Komposisi farmasi
EE9800209A (et) Antiglükokortikoidne ravimaine
BR9710568A (pt) Composi- o farmac-utica contendo um antagonista 5Hht2c e um antagonista d2
ITMI962628A0 (it) Composizione farmaceutica
ID23531A (id) Komposisi farmasi
NO20015128D0 (no) Synergistiske virkninger av amlodipin og atorvastatin
BR9505130A (pt) Composto e composiçao farmacêutica
BR1101151A (pt) Compostos e composição farmacêutica
BR1100391A (pt) Composto e composição farmacêutica
HUP0004274A3 (en) Bispyrido-cycloheptane compounds and pharmaceutical compositions thereof
SE9703737D0 (sv) Pharmaceutical composition and use
BR1100838A (pt) Composto e composição farmacêutica
BR9500539A (pt) Composto farmacêutico e composição farmacêutica
BR1100755A (pt) composição farmacêutica
SE9601854D0 (sv) Farmaceutisk komposition
ID17133A (id) Komposisi farmasi

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1491193

Country of ref document: EP